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ABSTRACT 
Purpose: Approximately 15% of patients with hypothyroidism are dissatisfied with their treatment due to persistence of residual 
symptoms associated with hypothyroidism.  The purpose of this study was to compare thyroid symptoms using the hypothyroid 
symptom scale (HSS) in patients receiving stable thyroid therapy for 6 months to patients without hypothyroidism.  The HSS was used 
to identify the percentage of levothyroxine-treated hypothyroid patients with residual or persistent hypothyroid symptoms. 
Methods:  Patients included in the study had hypothyroidism and were receiving a stable/maintenance dose of levothyroxine sodium 
therapy, unchanged for at least 6 months.  A control group of patients were included if they did not have an active prescription for 
thyroid hormone therapy.  The HSS was administered via phone or face-to-face interactions.   Patients were asked to score 10 symptoms 
over the past month on a scale of 0 to 4 (e.g., 0, absence of, to 4, severe symptoms).  Results were analyzed using descriptive and 
inferential statistics.  T-tests and chi-squared analysis were used to assess differences in continuous and categorical variables. 
Results:  A total of 68% of the contacted patients responded to the survey.  A total of 302 patients were in the intervention group and 
273 were in the control group.  The mean total HSS scores between groups were significantly higher in the treatment compared to the 
control group (13.92 ± 10.91 vs.10.07 ± 7.85; P < 0.001). 
Conclusion: Significantly more patients receiving thyroid hormone therapy experienced residual thyroid symptoms compared to control 
patients.  Attempts should be made to offer alternatives for hypothyroid patients with persistent symptoms. 
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INTRODUCTION 
Current estimates indicate that hypothyroidism affects 5%-10% 
of adult women and 3% of men in the United States (US).1,2 
Overt hypothyroidism in the general population is between 
0.3% and 3.7% in the United States and between 0.2% and 5.3% 
in Europe.3 The target of therapy is to normalize serum TSH; 
however, measurement of T3 concentrations may be of greater 
physiologic importance.  There is a large interindividual 
variability of serum triiodothyronine (T3) levels, as well as, 
variability in levels with circadian rhythms.  Currently, it is 
unknown if variations in serum triiodothyronine concentrations 
within the reference range is of physiologic or clinical 
significance. Normalizing both TSH and T3 concentrations may 
be important in some situations. Future research should focus 
on developing more accurate assays to measure serum 
concentrations of FT3, total T3, and FT4.4 A recent study by 
Peterson et al. reported that as many as 15% of treated 
hypothyroid patients with a normal serum TSH level had 
approximately 15-20% lower serum T3:T4 ratios in LT4 
treatment. 5 
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In the recently published American Thyroid Association (ATA) 
guidelines for the diagnosis and treatment of hypothyroidism 
there was a consensus that dosing of levothyroxine should be 
guided by periodic TSH testing with the goal of therapy to yield 
levels within the therapeutic range between 0.4 - 4.0 mIU/L. 
However, there is controversy surrounding this range.4  Some 
experts feel that the value should be between 0.4 mlU/L and 
2.5 mIU/L.6  The authors of the guidelines did not recommend 
changing either levothyroxine doses or formulations of thyroid 
hormone replacement based upon symptoms.4,7 There are 
reports suggesting that normal thyroid function measures are 
not always indicative of “euthyroidism”.5  Peterson and 
colleagues found that patients treated with levothyroxine had 
higher body mass index (despite consuming fewer calories per 
day).5  Furthermore, Tan and colleagues evaluated Asian 
patients receiving levothyroxine replacement therapy in the 
community setting and found that a decreased quality of life 
(QOL) score was associated with hypothyroid patients with a 
single persistent symptom, including weight gain (adjusted OR 
[95% CI], 3.12 [1.71-5.68]), feeling weak (2.12 [1.09-4.11], and 
having dry or coarse skin (2.27 [1.24-4.14]), but decreased QOL 
was not associated with TSH or free thyroxine levels.8 
 
Thyroid related symptoms may be subtle and challenging to 
quantify yet serial measures of such symptoms in patients do 
support the utility of this approach to patient care.2,9-13 A 
previously reported ten Symptom Scale Instrument 
(Hypothyroid Symptom Scale, HSS) has shown its ability to 
quantify persistent symptoms in levothyroxine treated 
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patients.11,12 The purpose of this study was to compare thyroid 
symptoms using the hypothyroid symptom scale (HSS) in 
patients receiving stable thyroid therapy for 6 months to 
patients without hypothyroidism.  The HSS was used to identify 
the percentage of levothyroxine-treated hypothyroid patients 
with residual or persistent hypothyroid symptoms.13 
 
METHODS 
Study design  
Subjects were identified by Proxsys Rx retail pharmacy 
prescription database in eight health systems between July 
2017 and February 2018. Proxsys Rx, is a company that partners 
with hospital and health systems to fill pharmacy gaps that may 
exist. The retail pharmacies were integrated inside hospitals to 
provide bedside delivery and enhance employee benefits 
through cost savings.  Subjects were identified from 
prescription history at each location. Patients were included in 
the study if they had hypothyroidism and were receiving a 
stable/maintenance dose of levothyroxine sodium therapy.  
Stable/maintenance dose was defined as continuous 
unchanged levothyroxine sodium therapy for ≥ six months.  No 
serum thyroid measures were evaluated. Patients were 
excluded if they were receiving any non levothyroxine 
formulation of therapy. Use of antidepressants, psychoactive 
medications, statins, and presence of any cardiac disease was 
recorded.  
 
Proxsys Rx identified patients who met the inclusion criteria 
based on whether or not patients had an active prescription for 
levothyroxine for at least six months.  A random control group 
of patients were included who did not have an active 
prescription for levothyroxine; no thyroid measures were 
evaluated and patients were not known to have thyroid 
disease.  Patients were not matched on the basis of age or 
gender. Once identified, eligible patients were contacted by 
telephone and the HSS was administered between February 3 
and June 15, 2018.  A script was prepared to assist personnel 
with maintaining consistency between calls.  Responses were 
recorded in an online tool.14 
 
A total of six questions were asked of the patients including 
whether or not they were currently taking levothyroxine, 
current use of other medications, current treatment for heart 
disease, high cholesterol, high blood pressure, mood disorder, 
or none of these conditions.  In addition, patients were asked 
to complete the HSS to determine whether they experienced 
the following symptoms over the past month: dry skin, fatigue, 
weight gain, cold weather intolerance, constipation, muscle 
stiffness, puffiness, memory loss, feeling blue, or dizziness.  The 
severity of each sign and symptom was rated on a scale from 0 
to 4 points with the following numerical designations: absent 
(0), minimal (1), mild (2), moderate (3), and severe (4).  The item 
scores were totaled to obtain the sum of signs and symptoms, 
which could range from 0 to 40 points. A HSS score >10 was 
used to assess residual symptoms as previous reports have 
shown that the upper limit of total symptoms for normal 
control subjects was 10.84 +/- 0.75. A copy of the questionnaire 
is provided in Appendix 1. 
 
The Institutional Review Board of Samford University reviewed 
and provided the ethics approval for this study, and the study 
procedures were in accordance with the ethical standard. 
Participation in the study was voluntary and anonymous. 
Participants were informed about the purpose and the protocol 
of the study. 
 
Statistical Analysis 
Descriptive statistics were employed to summarize all variables 
with means and standard deviations presented for continuous 
variables and frequencies and proportions for categorical 
variables. T-tests were used to detect differences between two 
groups for continuous variables. Chi-square tests were used to 
assess associations between categorical variables. No 
demographic information was captured with the questionnaire 
and no analysis was conducted on the basis of demographic 
information.  All analyses were conducted using STATA 
statistical software package (version 12; StataCorp LP, College 
Station, TX, USA). 
 
In order to enhance enrollment, the protocol was amended 
during the recruitment phase to allow for patients to complete 
a paper-based evaluation that was transcribed into the survey 
instrument, in addition to the telephonic questionnaire. The 
amendment was approved by the Samford University 
Institutional Review Board. 
 
RESULTS 
A total of 839 of 999 eligible patients were contacted to 
generate a random sampling of eligible individuals.  A total of 
575 patients responded to the survey, yielding a 68% response 
rate. The treatment group consisted of 302 patients and the 
control group consisted of 273 patients.  Complete data was 
obtained from 301 patients in the treatment group and 261 
patients in the control group.  Table 1 displays the distribution 
of HSS study participants by pharmacy.  An independent t-test 
was used in the sample of responders to determine if there 
were differences in symptom scores between levothyroxine 
(the treatment group) patients and the control group. The 
results are reported in Table 2. The mean HSS scores were 
significantly higher in the treatment than the control group 
(13.92 ± 10.91 vs.10.07 ± 7.85; P < 0.001). The treatment group 
had statistically significant higher scores in 9/10 symptoms 
compared to the control group. The prevalence for the 
following symptoms were significantly higher in the treatment 
group compared to the controls: dry skin (P <0.001), fatigue (P 
<0.001), cold weather intolerance (P <0.01), constipation (P 
<0.05), muscle stiffness (P <0.05), puffiness (P <0.05), memory 
loss (P <0.05), feeling blue (P<0.05), and dizziness (P<0.01).  
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The distribution of the ten individual symptom items in the 
control and levothyroxine treated groups, were examined and 
plotted in Figure 1.  Individualized mean scores were higher 
across all symptoms in the treatment group compared to the 
control group.  
 
Table 3 shows the proportion of responding subjects with self-
reported medication use and comorbidities. Among the 
responders, self-reported use of medications for comorbidities 
was higher in the treatment group compared to the control 
group (80.1% vs. 60.2%; P <0.0001), with significant differences 
in heart disease, high cholesterol, high blood pressure (all P-
values were <0.0001), but not mood disorder (P > 0.05).  We 
determined the percentage of patients in both groups with 
symptoms score above the average score of controls (10.07).  
The difference between groups was 20% (64% of the treatment 
group and 44% of the control group).  A total of 192 (63.5%) 
patients receiving levothyroxine, and 116 (44.4%) patients in 
the control group had scores > 10 on the HSS.  No analysis was 
conducted to evaluate the impact of concomitant medications 
and HSS scores in patients with comorbid conditions. 
 
DISCUSSION 
The HSS has previously been described and compared to other 
scoring systems in the clinical assessment of the adequacy of 
thyroid hormone replacement therapy in patients with 
hypothyroidism.15,16 Using this scale, authors of the present 
study showed that patients treated for hypothyroidism 
continue to experience significantly more symptoms commonly 
associated with thyroid disorder compared to patients who 
have not been diagnosed or treated with levothyroxine for 
hypothyroidism. This study confirmed the results of a previous 
one in which patients with hypothyroidism, and who were 
receiving levothyroxine treatment, were compared with 
euthyroid patients.15  In the study by Carle et al., patients with 
overt hypothyroidism were compared with individually 
matched control subjects. Patients filled out questionnaires 
regarding hypothyroid symptoms.  Patients with 
hypothyroidism reported more tiredness (81%), dry skin (63%), 
and shortness of breath (51%).  The highest ORs were reported 
for tiredness, OR, (5.94 (3.7-9.60), hair loss, OR, (4.58 (2.80-
7.51)), and dry skin, OR, (4.09 (2.73-6.16). 15  In the current 
study, the sum of symptom scores for the control group was 
10.07 ± 7.85 vs. 13.92 ± 10.91; P<0.001. Singh and colleagues 
also found that optimal levothyroxine replacement improves 
symptoms of hypothyroidism. Patients receiving levothyroxine, 
titrated to a serum TSH range between 0.4 – 4.5 mIU/L, 
experienced a significant decrease in symptoms (e.g., lack of 
energy, dry skin, constipation, aches and pains, cold 
intolerance, poor memory, depression, weight gain, tiredness 
while walking, and difficulty getting up) after treatment. 17 
 
Peterson and colleagues evaluated dissatisfaction with 
hypothyroid therapy in 12,146 patients.18 Their study reported 
differences in satisfaction among patients receiving different 
formulations of thyroid hormones.  Patients taking desiccated 
thyroid extract (DTE) reported a higher median treatment 
satisfaction of 7 (IQR, 5-9) compared to other treatments. 
Patients receiving LT4 treatment reported a lower satisfaction 
score of 5 (IQR 3-7), while those receiving LT4 + LT3 reported a 
higher satisfaction score of 6 (IQR, 3-8). Patients taking DTE 
were less likely to report problems related to weight 
management, fatigue/energy levels, mood, and memory 
compared to patients taking other agents.  The authors 
suggested that additional studies be conducted to better 
determine the therapeutic basis for this finding. 18 
 
Although patients with comorbid disease states (e.g., high 
cholesterol, heart disease, hypertension) experienced more 
symptoms such as weight gain, fatigue, and dizziness, no 
inferences can be made why this phenomenon occurred other 
than these patients were generally less healthy than the other 
patients.  However, the diagnosis of hypothyroidism may have 
exacerbated some of these conditions as 
untreated/undertreated hypothyroidism is associated with 
these symptoms.  No significant differences were found in 
patients with mood disorders; however, the study was not 
powered to detect these differences.   
 
There are several potential limitations to this study. 
Information on patient demographics was not collected (e.g., 
age, gender, ethnicity) and the ability to conduct a more 
thorough analysis was reduced. There could potentially be 
some gender, ethnic, or age variation in response to therapy 
that was not captured with the symptom assessment scale 
instrument used in the study. Since patient’s literacy levels 
were not evaluated, it is unknown whether the baseline or 
health literacy levels in the patient population would have 
affected their ability to properly complete the survey.  The 
investigators did not capture information on whether or not the 
respondents were euthyroid prior to the study. If patients were 
not adequately treated or they were taking medications that 
may have interfered with levothyroxine absorption, they may 
still suffer from residual hypothyroid symptoms.  However, 
information related to adherence to thyroid therapy was not 
attained.  There may have been some selection bias as patients 
who were experiencing residual thyroid symptoms may have 
been more prone to being included in the study.  In addition, 
the clinical significance of differences in the HSS between 
intervention and control patients are not known.  Additional 
studies should evaluate the clinical impact of score differences 
on health-related quality of life. 
 
CONCLUSION 
In conclusion, hypothyroidism is a common, yet complex, 
condition with a wide spectrum of presentation and symptoms. 
Assessing symptoms, and health status is essential in optimally 
managing and monitoring the condition. These study results 
indicate that as many as 15-20% of patients who were receiving 
a stable dose of levothyroxine, may have residual symptoms 
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and form the subset for therapeutic trials using novel therapies. 
The HSS may be beneficial in helping to identify patients who 
may continue to have residual thyroid symptoms regardless of 
thyroid therapy.  Additional studies need to be conducted to 
determine the clinical significance of differences in the HSS. 
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Table 1:  Distribution of HSS study participants by Pharmacy 
Pharmacies Contacted 
Completed 
(phone) Emailed Declined Mailed 
Non 
Candidate 
Pharmacy 1 117 12 7 0 4 1 
Pharmacy 2 91 17 9 4 1 0 
Pharmacy 3 122 23 17 5 3 2 
Pharmacy 4 72 14 7 7 0 0 
Pharmacy 5 99 18 10 5 1 1 
Pharmacy 6 170 29 6 12 1 2 
Pharmacy 7 43 11 2 4 1 4 
Pharmacy 8 125 34 15 0 4 0 
       
Total 839 158 73 37 15 10 
 
 
Table 2:  Differences in symptom score between treatment and control patients 
 
Symptoms Control (n=273)  Treatment (n=302) P-value 
Sum of symptoms 10.07 ± 7.85 13.92 ± 10.91 <0.001 
Dry Skin  1.26 ± 1.16 1.75 ± 1.36 <0.001 
Fatigue 1.64 ± 1.28 2.05 ± 1.41 <0.001 
Weight Gain 1.34 ± 1.31 1.44 ± 1.46 >0.05 
Cold Weather Intolerance 1.15 ± 1.36 1.65 ± 1.43 <0.001 
Constipation 0.95 ± 1.2 1.22 ± 0.33 <0.05 
Muscle Stiffness 1.18 ± 1.3 1.57 ± 1.46 <0.01 
Puffiness 0.70 ± 1.06 1.16 ± 0.3 <0.001 
Memory Loss 0.72 ± 1.08 1.13 ± 0.29 <0.001 
Feeling Blue 0.91 ± 1.17 1.11 ± 0.26 <0.05 
Dizziness 0.63 ± 0.95 0.87 ± 0.15 <0.01 
Mean ± SD 
SD, standard deviation, 
Note: Statistical tests of significance performed using the t-test 
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Figure 1: Distribution of individual symptom score 
  
 
 
 
 
 
 
Table 3:  Proportion of responding subjects with self-reported medication use and medical comorbidities 
  Control (n=269) Treatment (n=301)   
Condition n (%) n (%) P-value 
Currently taking other medications 162 (60.2) 266 (80.1) <0.0001 
Heart disease  9 (3.3) 38 (12.6) <0.0001 
High cholesterol 36 (13.2) 95 (31.5) <0.0001 
High blood pressure 71 (26.0) 153 (50.7) <0.0001 
Mood disorder 41 (15.0) 59 (20.0) >0.05 
At least one condition 109 (40) 207 (69) <0.0001 
Not being treated for any of the above 164 (60.1) 95 (31.5) <0.0001 
Tests of statistical significance performed 
using Chi-square test. 
 
Percentages are row percentages.    
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Appendix I: Hypothyroid Symptom Scale Survey 
 
1. Do you agree to the above terms?  By clicking Yes, you consent that you are willing to answer the questions in this survey. 
 
A. Yes  
B. No 
 
2.  Are you currently taking any medications? 
 
A. Yes  
B. No 
 
3.  Are you currently being treated for any of the following conditions?  (Check all that apply). 
 
A. Heart disease 
B. High cholesterol 
C. High blood pressure 
D. Mood disorder 
E. None of the above 
 
4.  Please indicate the severity to which you have experienced the condition over the past month on a scale of 0 to 4 (absent =0, 
minimal = 1, mild = 2, moderate =3, and severe =4). 
 
A. Dry skin 
B. Fatigue 
C. Weight gain 
D. Cold weather intolerance 
E. Constipation 
F. Muscle stiffness 
G. Puffiness 
H. Memory loss 
I. Feeling blue 
J. Dizziness 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
